BOLT
Bolt Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.25
−4.87%Oct 23, 2026, 14:37 UTC
Bolt Biotherapeutics appointed Sheila Gujrathi as a Class II director and Chief Strategy Officer, effective October 23, 2026.
Oct 6, 2026, 20:14 UTC
Bolt Biotherapeutics amended its lease with HCP LS Redwood City LLC, accelerating the lease expiration to December 31, 2027, or earlier upon a Corporate Transaction, and providing for a $4.5 million termination payment upon such a transaction.
Aug 11, 2026, 20:05 UTC
Bolt Biotherapeutics reported its financial results for the second quarter ended June 30, 2026, and provided a business update.
Source: